<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04278989</url>
  </required_header>
  <id_info>
    <org_study_id>PRO00037907</org_study_id>
    <nct_id>NCT04278989</nct_id>
  </id_info>
  <brief_title>Inhibition of Oral Tumorigenesis by Antitumor B</brief_title>
  <official_title>Inhibition of Oral Tumorigenesis by Antitumor B</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Medical College of Wisconsin</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Medical College of Wisconsin</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a randomized, double-blinded, placebo-control window of opportunity study of&#xD;
      Anti-tumor B versus placebo. Anti-tumor B is a botanical agent composed of six Chinese herbs:&#xD;
      Sophora tonkinensis, Polygonum bistorta, Prunella vulgaris, Sonchus brachyotus, Dictamnus&#xD;
      dasycarpus, and Dioscorea bulbifera.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      One of the most promising chemopreventive agents to prevent head and neck cancer is Antitumor&#xD;
      B (ATB), a Chinese herbal mixture.&#xD;
&#xD;
      This randomized Window of Opportunity trial will enroll patients with resectable stage I-IVB&#xD;
      squamous cell cancer of the oral cavity who are candidates for surgical tumor resection.&#xD;
      Participants will agree to allow a portion of the standard of care (diagnostic tumor biopsy)&#xD;
      to be used for the study, and to take study agents or placebo for a duration (14 to 21 days)&#xD;
      until the time of their surgery. A second, post-treatment tumor biopsy is not needed because&#xD;
      the OR-resected tumor will serve this purpose.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">September 1, 2021</start_date>
  <completion_date type="Anticipated">December 1, 2024</completion_date>
  <primary_completion_date type="Anticipated">December 1, 2023</primary_completion_date>
  <phase>Early Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Care Provider, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Tumor Ki-67 in baseline tumor biopsy compared to resected tumor.</measure>
    <time_frame>Baseline and following surgery (seven to 28 days after baseline)</time_frame>
    <description>KI-67 will be measured as a change in the index from baseline to post-treatment (surgery).</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">28</enrollment>
  <condition>Squamous Cell Cancer of the Oral Cavity</condition>
  <arm_group>
    <arm_group_label>Anti-tumor B</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>1,200 mg three times a day.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo taken three times a day.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Anti-tumor B</intervention_name>
    <description>1,200 mg, three times a day for seven to 28 days (dependent on scheduled surgery).</description>
    <arm_group_label>Anti-tumor B</arm_group_label>
    <other_name>Zeng-Sheng-Ping</other_name>
    <other_name>ACAPHA</other_name>
    <other_name>ATB</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebos</intervention_name>
    <description>Placebos taken seven to 28 days (dependent on scheduled surgery).</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Voluntary written consent must be given before performance of any study-related&#xD;
             procedure not part of standard medical care, with the understanding that consent may&#xD;
             be withdrawn by the subject at any time without prejudice to future medical care.&#xD;
&#xD;
          2. Clinical diagnosis of oral cavity squamous cell cancer.&#xD;
&#xD;
          3. Patient can start study agent administration but histological confirmation of squamous&#xD;
             cell cancer (SCC) of the oral cavity (or histologic variants of SCC) by the&#xD;
             pathologist must happen within seven days of registration in order to continue&#xD;
             protocol therapy.&#xD;
&#xD;
          4. Clinical stage II-IVA (as defined by the American Joint Committee on Cancer (AJCC),&#xD;
             8th Edition), and amenable to surgical resection.&#xD;
&#xD;
          5. New diagnosis of oral SCC, new second primary, or recurrent oral SCC following a&#xD;
             minimum remission of six months following previous definite surgery.&#xD;
&#xD;
          6. History and physical examination by an otolaryngologist and medical oncologist within&#xD;
             14 calendar days of study registration.&#xD;
&#xD;
          7. Zubrod/ECOG Performance status &lt; 2.&#xD;
&#xD;
          8. Age ≥ 18 years.&#xD;
&#xD;
          9. Complete Blood Count (CBC)/differential obtained within 14 calendar days prior to&#xD;
             registration, with adequate bone marrow function defined as follows:&#xD;
&#xD;
               -  Absolute neutrophil count (ANC) ≥ 1,500 cells/mm^3;&#xD;
&#xD;
               -  Platelets ≥ 100,000 cells/mm3;&#xD;
&#xD;
               -  Hemoglobin ≥ 8.0 g/dl (Note: The use of transfusion or other intervention to&#xD;
                  achieve Hgb ≥ 8.0 g/dl is acceptable).&#xD;
&#xD;
         10. Adequate renal and hepatic function within 14 calendar days prior to registration,&#xD;
             defined as follows:&#xD;
&#xD;
               -  Serum creatinine &lt; 1.5 mg/dl or creatinine clearance (CCr) ≥ 50 ml/min within 14&#xD;
                  calendar days prior to registration, determined by 24-hour collection or&#xD;
                  estimated by Cockcroft-Gault formula:&#xD;
&#xD;
               -  CCr male = [(140 - age) x (wt in kg)]&#xD;
&#xD;
               -  [(Serum Cr mg/dl) x (72)]&#xD;
&#xD;
               -  CCr female = 0.85 x (CrCl male)&#xD;
&#xD;
         11. Total bilirubin &lt; 2 x the institutional upper limit of normal (ULN);&#xD;
&#xD;
         12. Aspartate aminotransferase (AST) or alanine aminotransferase (ALT) ≤ 3 x the&#xD;
             institutional ULN;&#xD;
&#xD;
         13. Magnesium, calcium, glucose, potassium, and sodium within 14 calendar days prior to&#xD;
             registration, with the following required parameters:&#xD;
&#xD;
               -  Magnesium: &gt; 0.9 mg/dl or &lt; 3 mg/dl;&#xD;
&#xD;
               -  Calcium: &gt; 7 mg/dl or &lt; 12.5 mg/dl;&#xD;
&#xD;
               -  Glucose: &gt; 40 mg/dl or &lt; 250 mg/dl;&#xD;
&#xD;
               -  Potassium: &gt; 3 mmol/L or &lt; 6 mmol/L;&#xD;
&#xD;
               -  Sodium: &gt; 130 mmol/L or &lt; 155 mmol/L.&#xD;
&#xD;
         14. Eastern Cooperative Oncology Group (ECOG) performance status of 0 to 2.&#xD;
&#xD;
         15. Female subjects must meet one of the following:&#xD;
&#xD;
               -  Postmenopausal for at least one year before enrollment, OR&#xD;
&#xD;
               -  Surgically sterile (i.e., undergone a hysterectomy or bilateral oophorectomy), OR&#xD;
&#xD;
               -  If subject is of childbearing potential (defined as not satisfying either of the&#xD;
                  above two criteria), agrees to practice two acceptable methods of contraception&#xD;
                  (combination methods require use of two of the following: diaphragm with&#xD;
                  spermicide, cervical cap with spermicide, contraceptive sponge, male or female&#xD;
                  condom, hormonal contraceptive) from the time of signing of the informed consent&#xD;
                  form through 21days after the last dose of study agent, OR&#xD;
&#xD;
               -  Agrees to practice true abstinence when this is in line with the preferred and&#xD;
                  usual lifestyle of the subject. (Periodic abstinence [e.g., calendar, ovulation,&#xD;
                  symptothermal, postovulation methods] and withdrawal are not acceptable&#xD;
                  contraception methods.)&#xD;
&#xD;
         16. Male subjects, even if surgically sterilized (i.e., status postvasectomy), must agree&#xD;
             to one of the following:&#xD;
&#xD;
               -  Practice effective barrier contraception during the entire study period and&#xD;
                  through 60 calendar days after the last dose of study agent, OR&#xD;
&#xD;
               -  Agree to practice true abstinence when this is in line with the preferred and&#xD;
                  usual lifestyle of the subject. (Periodic abstinence [e.g., calendar, ovulation,&#xD;
                  symptothermal, postovulation methods] and withdrawal are not acceptable methods&#xD;
                  of contraception.)&#xD;
&#xD;
         17. Enrollment on an interventional postoperative study is allowed if study agents do not&#xD;
             overlap.&#xD;
&#xD;
         18. Gastric tube drug administration is permissible.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Pregnant or lactating women are ineligible due to unforeseeable risks to embryo or&#xD;
             fetus.&#xD;
&#xD;
          2. Concurrent use of any medicinal botanical, natural, or other herbal compounds.&#xD;
&#xD;
          3. Planned subtotal or debulking surgery is not permissible.&#xD;
&#xD;
          4. Prior systemic chemotherapy for oral SCC; note that prior chemotherapy for a different&#xD;
             cancer is allowable.&#xD;
&#xD;
          5. Prior radiotherapy for oral SCC is permissible if disease free for one year since&#xD;
             prior oral cancer treatment and free of significant late radiation effects.&#xD;
&#xD;
          6. Severe active comorbidity, such as uncontrolled cardiac disease, infection, and severe&#xD;
             chronic obstructive pulmonary disease (COPD).&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Stuart J Wong, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Medical College of Wisconsin</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Medical College of Wisconsin Cancer Center Clinical Trials Office</last_name>
    <phone>414-805-8900</phone>
    <email>cccto@mcw.edu</email>
  </overall_contact>
  <location>
    <facility>
      <name>Froedtert Hospital &amp; the Medical College of Wisconsin</name>
      <address>
        <city>Milwaukee</city>
        <state>Wisconsin</state>
        <zip>53226</zip>
        <country>United States</country>
      </address>
    </facility>
    <contact>
      <last_name>Medical College of Wisconsin Cancer Center Trials Office</last_name>
      <phone>414-805-8900</phone>
      <email>cccto@mcw.edu</email>
    </contact>
    <investigator>
      <last_name>Stuart J. Wong, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>June 2021</verification_date>
  <study_first_submitted>February 19, 2020</study_first_submitted>
  <study_first_submitted_qc>February 19, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">February 20, 2020</study_first_posted>
  <last_update_submitted>July 16, 2021</last_update_submitted>
  <last_update_submitted_qc>July 16, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">July 20, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Medical College of Wisconsin</investigator_affiliation>
    <investigator_full_name>Stuart Wong</investigator_full_name>
    <investigator_title>Professor</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Neoplasms, Squamous Cell</mesh_term>
    <mesh_term>Carcinoma, Squamous Cell</mesh_term>
    <mesh_term>Carcinogenesis</mesh_term>
    <mesh_term>Cell Transformation, Neoplastic</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

